KZIA
Companies
NASDAQ
Kazia Therapeutics Ltd Sponsored ADR
Health Care
$9.07
+$0.22 (+2.49%)
Price Chart
Overview
About KZIA
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Market Cap
$7.4M
Volume
200.5K
Avg. Volume
322.1K
P/E Ratio
-27.16535470617099
Dividend Yield
0.00%
Employees
34.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.91
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, KZIA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$7.4M
Volume200.5K
P/E Ratio-27.17
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
October 17, 2022Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025